News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Elsevier launches Complete Anatomy female model, the most advanced full female anatomy model available in the world

Elsevier

The innovative 3D solution marks a major milestone in education equality with the representation of the full female anatomy in the study of the human body The launch is coming at a time when females are more likely to be misdiagnosed for health conditions compared to male counterparts Elsevier, a global leader in research publishing and information analytics, is pleased to announce the launch of the most advanced 3D full female model ever available, as part of the latest addition to its 3D platform, Complete Anatomy. This marks the first time that a female model has been built with this level of detail in its entirety, to represent the female — versus replacing specific areas of the male anatomy with female features. The solution allows educators to visualize, edit and teach anatomy entirely from the female perspective for the first time, all in stunningly realistic 3D detail. Complete Anatomy is a revolutionary cloud-based medical education platform from 3D4 Medical by Elsevier and is the No. 1 top-selling medical category app on iPad in the U.S., with over 20 million downloads globally. The launch signifies a major milestone in equal representation by preparing medical, nursing and allied health students with the most complete understanding of the female anatomy. Historically, the full female anatomy has been underrepresented in the study of the human body. Now, educators can choose the sex with which they’d like to teach their full curriculum, in addition to having the option of switching between male and female anatomies to teach comparative differences in sex-specific regions of the body. The Complete Anatomy female model provides educators with a more comprehensive teaching approach that allows them to switch seamlessly between teaching both female and male anatomy. Elizabeth Munn, Managing Director, Global Medical Education, Elsevier, said: “As an advocate for content that is diverse and inclusive, we are thrilled to offer this groundbreaking full female model to allow educators to teach anatomy in an equal and comprehensive way. Complete Anatomy is continuing Elsevier’s rich heritage of innovation in education by delivering on our vision of providing transformative medical education solutions. We are proud to take this step forward in addressing gender bias and believe Complete Anatomy’s female model will have a tremendous impact on the educational experience of medical students worldwide as well as on the outcomes of patients they treat in the future.” Informed by four years of expert research and development, anthropological data from specialist texts, academic papers and customer feedback, the addition of the female model to Complete Anatomy’s 3D platform provides an unprecedented opportunity to study the female form in more detail than before. Complete Anatomy’s female model will benefit all courses that teach anatomy and is an essential virtual tool for learners studying outside the lab who need a deeper understanding of both male and female anatomies. The Complete Anatomy female model includes: The full skeletal system — A complete female skeletal system includes a wide array of unique features, rarely seen in anatomical texts. Sexual differences have been applied to areas such as the pelvis and skull. Long bones have been proportioned, and bone angles accurately reflect the uniquely female architectural skeletal base. Accurate portrayal of muscles — To create an accurate representation of the female anatomy, the overall volume of muscle mass for each muscle has been reduced by roughly 30%, in line with research findings from the broadest demographic of females as compared to males. Visually detailed female-specific regions — The female-specific regions have been created in detail that is equivalent to the male counterpart. Breast tissue can be hemisected or quartered to reveal the underlying tissues with a more accurate distribution and representative state of the mammary glands, now shown as nonlactating, unlike most anatomical resources. The reproductive organs from the internal and external genitalia have been remodeled to accurately show their continued relationship. Comparative functionality — Users can switch between models for comparative study on any part of the male and female forms, compare sexual differences and reveal the origin and distribution of nerves. Users can learn continuity from a “Gray’s Anatomy”-inspired atlas and dissection course, take quizzes and watch videos to test their skills. Lead subject matter expert on the update Yasmin Carter, PhD, Assistant Professor of Translational Anatomy at the UMass Chan Medical School, Worcester, MA, USA said: “One of the inherent dangers in using only the male body as ‘anatomical normal’ and the female body as a variation, is perpetuating sexist attitudes. This unconscious bias will be carried by learners into their future interactions with the body, including potentially with patients. Complete Anatomy is creating a platform of representation that is diverse, balanced, and most importantly, accurate. By giving educators the option to choose the female body as the basis for their students’ education, Elsevier is helping evolve equitable teaching practices by normalizing the female body. Complete Anatomy’s female model will support me in training the next generation of medical professionals to be more appropriate and inclusive.” Elsevier has been working continuously to enhance its global portfolio of medical education solutions, digital learning tools and analytics for medical and nursing students to prepare them for successful careers in health professions. Recently, Elsevier announced the acquisition of Osmosis, a visual learning platform for medical students and professionals, which followed other acquisitions in nursing and health education, including Shadow Health, a developer of virtual nursing simulations, and the 2019 acquisition of 3D4 Medical, the creator of the Complete Anatomy app. In addition, Elsevier launched ClinicalKey Student, an interactive medical education platform equipped with learning tools to support both students and faculty. --- About Complete Anatomy Complete Anatomy from 3D4 Medical by Elsevier is the world's most advanced 3D anatomy platform. The revolutionary cloud-based education platform allows users to investigate the minute detail of the human anatomy in incredible 3D. Complete Anatomy is transforming medical learning and practice across the world, leading the way in the production of groundbreaking 3D medical technology. Featuring over 2.5 million registered customers and over 20 million downloads globally, Complete Anatomy is used daily in over 350 top universities around the world as well as with global clinical organizations. Complete Anatomy’s award-winning software has been featured on stage at Apple and Microsoft events, was honored as the Winner of the Apple Design Awards in 2016, and is the No. 1 top-selling medical category app on iPad in the U.S. 3D4 Medical has been developing medical and anatomical products since 2009 and was acquired by Elsevier in 2019. 3D4 Medical by Elsevier has continued to provide industry-leading innovations that have allowed new ways for students, educators and those in the medical community to learn and understand the human anatomy. To learn more about Complete Anatomy’s female model and the experience it provides users, please visit the 3D4 website. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Media contact Teresa Mueller, Vice President, Global Health Markets Elsevier Communications t.mueller@elsevier.com Contact Details Elsevier Communications Teresa Mueller, Vice President, Global Health Markets +31 6 20987384 t.mueller@elsevier.com Company Website https://www.elsevier.com/

January 10, 2022 09:00 AM Eastern Standard Time

Image
Article thumbnail News Release

McDade Products, LLC Joins Forces with G Medical Tests and Services to Provide U.S. Retailers with Millions of COVID-19 at-Home PCR Test Kits

G Medical Innovations Holdings

FDA EUA-approved PCR collection kit tests provide 24-hour certified lab results and retail for $9.99 In response to a national shortage of COVID-19 test options, Pittsburgh-based McDade Products, LLC has partnered with G Medical Tests and Services, a division of G Medical Innovations Holdings Ltd. (NASDAQ: GMVD), to manufacture several million U.S. FDA Emergency Use Authorization (EUA) approved COVID-19 PCR collection test kits available for retailers for sale by the end of January, 2022. McDade Products is a division of McDade Group, a specialty sales, marketing, and distribution company serving the U.S. retail industry. McDade Products is now accepting orders for the co-branded LiveNow PCR Collection Kit, which will retail for $9.99. The diagnostic PCR (polymerase chain reaction) test detects the presence or absence of SARS-CoV2, the virus that causes COVID-19. Users register with the lab online, collect a nasal swab sample at home, and send the sample to G Medical’s CLIA-certified lab with the pre-paid return pack. On average, tests results are expected to be available online within 24 hours from the time the sample is received. G Medical’s labs are approved by the FDA under the EUA. Currently, G Medical has two CLIA-certified labs; one in Southern California, and the other in North Carolina. In addition, G Medical has launched six testing centers in California, with many more planned. G Medical’s labs are capable of being run 24 hours per day 7 days a week, and can each process up to 24,000 COVID tests per hour to meet the current demand. The first test kit order is for 4 million units. G Medical will be selling these units wholesale for $3.25 each, reflecting gross profit of $7 million. Additionally, G Medical expects to be paid an average of $85.00 per test through each patient’s insurance. According to Grand View Research (grandviewresearch.com) the global PCR and real time PCR molecular diagnostics market was valued at over USD $23.6 Billion in 2020 and expected to expand at a CAGR (compound annual growth rate) of 0.9% between 2021 and 2028. “For decades, we’ve been committed to empowering clinicians and patients to better manage their health outcomes. By partnering with McDade Products, we can make our SARS-CoV2 certified lab testing accessible and convenient for customers and retailers nationwide. With new cases abound, and the world grappling with PCR test shortages there is a tremendous opportunity to provide safety, and relief to the world economy with a significant financial benefit to our shareholders,” said Dr. Yacov Geva, President and CEO of G Medical Innovations. “As a trusted and established next-generation mobile health and e-health company that provides clinical and consumer medical-grade health monitoring solutions, G Medical Innovations enables us to offer our retail customers with an end-to-end solution to address the national shortage of reliable COVID-19 diagnostic tests,” said Michael McDade, CEO of McDade Products, LLC. Visit https://www.mcdadegrp.com/ to place orders for the LiveNow PCR Collection Kits. About McDade Group Founded in 1994, McDade Group is a growing and dynamic sales, marketing, and distribution services company headquartered in Pittsburgh, PA. The company has expanded to provide solutions in distribution, category management, full-service merchandising, and consulting across the U.S. retail industry. Many of the world’s leading CPG manufacturers rely on the ability of McDade Group to build strong industry relationships and deliver services, insights, and expertise for hundreds of their products. Visit: https://www.mcdadegrp.com/ or LinkedIn: https://www.linkedin.com/company/mcdade-group/. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on G Medical’s and McDade Products’ current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of G Medical and McDade Products could differ materially from those described in or implied by the statements in this press release. For example, G Medical is using forward-looking statements when it discusses delivery of purchase orders, plans to open Covid-19 testing centers in California, timing of the delivery of tests results, anticipated gross profits, financial benefit to shareholders, and addressing the national shortage of reliable COVID-19 diagnostic tests. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. Investor Relations CONTACT: G Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com McDade Products, LLC Jennifer Faines 412-559-2860 Jennifer.faines@gmail.com Contact Details G-Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 Service@gmedinnovations.com Company Website https://gmedinnovations.com/

January 10, 2022 07:00 AM Eastern Standard Time

Article thumbnail News Release

Outstanding Preliminary Results of A Clinical Trial Treating Moderate-To-Severe Covid-19 Patients, Conducted By Amorphical, An Israeli Biotechnology Company

Amorphical

Amorphical’s Novel COVID-19 Oral and Inhaled Amorphous Calcium Carbonate (ACC) Treatment Significantly Reduces the Risk of ICU Admission and Mortality in Interim Analysis of a Phase II Study Involving Patients Hospitalized with Moderate-to-Severe COVID-19. (NIH Clinical Trial Registration No. NCT04900337) Outstanding preliminary results were revealed in an interim analysis of an on-going Phase II clinical study in Israel for treating patients with moderate-to-severe COVID-19. AMOR-18, a new drug consisting of Amorphical’s unique amorphous calcium carbonate (ACC), was the active pharmaceutical ingredient. The preliminary analysis focused onAMOR-18’s capability of stopping the currently-acute pandemic urgencies from further harming hospitalized patients. Out of a total of 37 patients recruited in one of the study centers, none of the 18 patients taking the drug was transferred to an intensive care unit (ICU) and all were released within a few days from the hospital. In a sharp contrast, 32% of the 19 participants in the placebo group, were transferred to ICU and 10% died. Thus far, sixty-six (66) patients were treated, six (6) in Phase I, fifty-eight (58) in Phase II and two (2) in a compassionate care program. The interim analysis is performed in one of the 4 participating medical centers (Ziv Medical Center) in which 37 moderate-to-severe patients had participated in a randomized, placebo controlled, double-blind study.19 patients were treated with placebo, and 18 patients with AMOR-18. Last week, Amorphical announced that all 18 patients with COVID-19, hospitalized with moderate or severe symptoms, who had received the drug AMOR-18, have recovered and were discharged within a few days. None of the patients treated with the drug were transferred to the intensive care unit or died. By contrast, among the nineteen (19) individuals in the placebo arm, six (6) were transferred to intensive care, and two of them died.As a part of Amorphical’s compassionate care program, two other patients with gravely serious conditions were given the drug outside the study in the same hospital. Both have recovered and were discharged from the hospital. “Since none of the patients receiving the drug (AMOR-18) were transferred to intensive care or died, this interim outcome is a tremendous success for our patients and community”, said Dr. Nashat Abu Saleh, Co-Director of the Coronavirus Department at the Ziv Medical Center in Safed, Israel, where this phase II clinical trial was conducted. Positive Interim Results The ongoing Phase II study (AMCS-COVID-001) is a Prospective, Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, and Efficacy of ACC(named AMOR-18 ), taken daily sublingually and via inhalation administration, concomitantly with Best Available Care (BAT), compared to placebo and BAT. The first efficacy measure assesses the rate of change from baseline to study completion (hospital release or death), as defined by an improvement of 1 or more points on an ordinal 8-point scale. The second measure of efficacy is the ratio of mortality to Intensive Care Unit (ICU) admissions. The preliminary analysis was conducted on a total of 37 patients, equally randomized to treatment with either AMOR-18 (ACC) or a placebo, concomitantly with BAT. Six (6) out of the group of 19 patients (32%) treated with placebo concomitantly with BAT were transferred to the ICU, two of whom died (33%). Conversely, none of the hospitalized patients actively treated with ACC) were transferred to the ICU or died. Dr. Kamal Abu-Jabal, Co-Director of the Outpatient Hospital Unit and ICU COVID-19 Unit at Ziv Medical Center, said: "I believe this treatment has the potential to significantly reduce the mortality rate in patients with moderate-to-severe COVID-19 symptoms and has a broader potential for treating patients who contract similar viral infections. We found safety, effectiveness, and no side effects. Together with the treatment available today for COVID-19, Amor 18 may turn this pandemic to an illness from which one can recover relatively easily, even severely ill hospitalized patients. In our opinion, we are at a turning point of a fundamental change in dealing with COVID-19". Yossi Ben, Founder & CEO of Amorphical, noted: "The interim results bring a great deal of interest among countries and the scientific community. Amorphical is currently conducting several negotiations for such international participation in efforts to combat the pandemic. We intend to provide preferred distribution channels to countries who will support further clinical studies, as well as assist in obtaining regulatory related activities of the drug treatment". The Study at Glance Initially, 6 patients (not included in the reported 37) were recruited for a Training/Safety Study (Phase I) at 3 research hospital sites in Israel. This stage assessed the safety and administration protocol of AMOR- 18 in combined sublingual and inhalable modes. This part of the study concluded that it was safe to initiate a prospective, multicenter, randomized, double-blind, placebo-controlled phase II study. The study was originally designed to include 100 patients in total with one-on-one randomization (active + BAT vs. placebo + BAT), and conducting the Phase II study at four medical centers in Israel: Shamir, Ziv, Kaplan, and Mayanei Hayeshua. However, in December 2021, Amorphical conducted an interim analysis of the study on all 37 participating patients in one of the study institutions – Ziv Medical Center. The principal investigators at this Center are Dr. Kamal Abu-Jabal, and Dr. Nashat Abu-Saleh. The interim analysis was conducted due to the vast global spread of COVID-19, a temporary lack of patient candidates in Israel, and anurgent needfor opening study centers outside of Israel. The interim analysis was performed by an independent statistician. The Phase II study in Israel will continue to recruit the intended 100 patients at all the specified hospitals, potentially also including the Wolfson Medical Center-Israel. Preliminary Analysis The study population included 37 patients who tested positive for COVID-19 according to a PCR test and were hospitalized due to the severity of their conditions. After screening, 18 patients were randomly assigned to active treatment group and 19 to a placebo group. The ICU and mortality rate analysis was assessed, along with 95% Wilson Score Confidence Intervals (CI), comparing the study arms with a Cochran-Mantel-Haenszel Test. The Intent to Treat (ITT) analysis set consists of all subjects being randomized. In accordance with the ITT principle, subjects are kept/remain in their originally assigned treatment group. For subjects randomized for treatment by either ACC or placebo, the rate of ICU admittance or death occurred only in the placebo group, and was not observed in the treatment group (p<0.01).All patients in the ACC group tolerated the treatment well, were released from the hospital, and did not report any treatment-related adverse side effects. Further analysis of the interim resultsis on going. According to the preliminary analysis, subjects randomly placed in the active arm (ACC) had a statistically and significantly lower risk of death or ICU admission compared to those randomized into the placebo arm. In the active arm, 0.0% (0/18, 95% CI: [0.00%;17.59%]) of the subjects died or were transferred to the ICU, vs. 31.6% (6/19, 95% CI: 15.36%;53.99%]) in the placebo arm. This difference was highly significant, (p<0.02). The early analysis of the interim results concludes that treating moderate-to-severe COVID-19 hospitalized subjects with ACC AMOR-18is effective in reducing the risk of worsening of the disease. In addition to the goals outlined above, Amorphical has established a compassionate use program, which has treated two additional patients with very severe COVID-19 infection and significant comorbidities. Although these patients did not meet our study inclusion criteria, both responded well to the ACC treatment and were released home. Amorphical plans to complete phase II and immediately proceed to phase III. Phase III will further evaluate the effectiveness of ACC and confirm its safety, tolerability, and efficacy on a global scale. It will then be internationally submitted for prompt regulatory approvals with the intention to support the worldwide efforts against the current and similar future pandemics. Amorphical is currently engaged in approval process with ANVISA (the Brazilian Health Regulatory Agency) to begin recruitment for a similar study with 100 additional patients at 7 hospital sites in Brazil. About the ACC (AMOR-18) Therapeutic Mechanism ACC consists of nanometric and amorphous primary particles, and has much higher solubility & bioavailability than crystalline calcium carbonate (CCC). Amorphical successfully manufactures and markets several dietary supplements based on ACC, which help build, maintain, and restore the body’s health and strength. Preclinical and early clinical studies reveal that ACC provides unique therapeutic and biomedical activities for treating diseases and conditions, associated with acidosis conditionsby directly targeting specific organs or systems. There is a growing body of scientific literature indicating the effects of low pH (metabolic acidosisinside and around organs and cells) on: (a) the progression of SARS-type viruses in general, and COVID-19 in particular; (b) the detrimental impact of excessive acidity on lung inflammation and functions; and (c) the exaggerated immune response (expressed as a cytokine storm), leading to devastating lethal outcomes. In our current study, ACC aims to serve as a pH modulator of the extracellular compartment, inhibiting the virus cell’s penetration, and replication within body cells, and regulating abnormal immune responses. These therapeutic activities are enabled by ACC’s unique amorphous and nanometric state, combined with its carbonate component. These assumed therapeutic activities inspired the current clinical study for treating the entire range of patients suffering from mild-to-severe COVID-19 infection. About Amorphical Amorphical is an Israeli pioneering biotech company, established to develop health and therapeutic products based on amorphous calcium carbonate (ACC). Amorphical has succeeded in synthesizing, stabilizing, and preserving a naturally rare form of calcium carbonate used by nature’s most sophisticated “calcium-producing machine” – the blue crayfish. The synthesis and formulations have been scaled into a manufacturing GMP (Good Manufacturing Practices) operation for supplements in the Arava Desert in Israel. We develop novel solutions for numerous major diseases, based on the uniquely bioactive, nanometric and amorphous ACC. The company has applied for over 130 patent applications in over 40 countries, with over 60 patents already granted worldwide. ( www.amorphical.com )) Contact Details Amorphical Amorphical management info@amorphical.com Company Website https://www.amorphical.com/contact-us/

January 06, 2022 02:00 PM Eastern Standard Time

Image
Article thumbnail News Release

New COVID Testing Centers in Southeastern, North Carolina

COVID Testing Solutions

Today, COVID Testing Solutions™ announced the opening of eight new COVID-19 testing centers in Southeastern North Carolina. The eight new centers are located in Wake County, Asheboro, Southern Pines, Fayetteville, Rockingham, Laurinburg, Wilmington, and Jacksonville. Each center will collect saliva specimens for analysis using the company’s own PCR testing equipment. The goal is to deliver test results within 48-hours in the hope of reducing the spread of the virus. COVID Testing Solutions is prepared operationally to efficiently collect and test specimens from individuals and assist organizations, including churches, schools, and small and large organizations, with their COVID testing needs. The saliva-based (non-nasal probe) PCR test includes indirect indicators of viral load (i.e., level of infection) by measuring Thermal Cycles and can detect COVID-19 infection, regardless of strain, including the delta and omicron variants. The test is available at NO COST with or without insurance. COVID Testing Solutions is affiliated with COVID Treatment Clinics. COVID Treatment Clinics provides personalized, integrated plans that combine conventional and alternative treatment options. The physician-directed plans may include nutritional supplements, pharmaceuticals (monoclonal antibodies), oxygen therapy, and IV therapies. “COVID-19 is far from being contained. Our mission is to provide early testing and treatment that will save lives. Strengthening the immune system through early and individualized intervention is essential to reduce the short- and long-term impact of the disease.” James Taylor, MD COVID Testing Solutions/COVID Treatment Clinics Benefits of COVID Testing Solutions include: 1. No-cost saliva-based testing instead of the nose probe. 2. Quick results. 3. Indirect indicators of viral load which can help direct therapy. 4. Treatment options that go beyond mere bed rest and fluids. Dr. James Taylor created COVID Testing Solutions and COVID Treatment Clinics after his own bout with COVID-19. COVID testing is available today (January 6, 2022) at the Integrated Pain Solutions clinics in Asheboro, Southern Pines, Fayetteville, Rockingham, Laurinburg, Jacksonville, and Wilmington. A dedicated testing center is located in Wake County. COVID-related healthcare services are available for individuals, schools, employers, and organizations. To learn more, go to: COVID19testingsolutions.com or call 910-704-5299. Contact Details Gregory F. Toso +1 610-750-3039 Info@covidtreatmentclinics.com

January 06, 2022 12:00 PM Eastern Standard Time

Image
Article thumbnail News Release

Q-VANT Biosciences Launches to Solve the Pharmaceutical Industry Problem of Limited Quillaja Saponin-Based Adjuvants for Life-Saving Vaccines

Q-Vant Biosciences

Q-VANT Biosciences has launched as the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants including QS-21. QS-21 is considered the “Gold Standard” adjuvant for enhancing immune response to vaccine antigens and is a vital component in more than 17 human vaccine candidates, including the FDA-approved GSK Shingrix® shingles vaccine and the WHO-authorized, GSK Mosquirix® malaria vaccine. In addition, saponin-based adjuvants are a key component in the Novavax COVID-19 vaccine, which has been shown to be highly effective in clinical trials and has recently been authorized for emergency use by the European Union (EU) and the World Health Organization (WHO). Q-VANT is led by a team with world-class knowledge of vaccine and adjuvant development, Quillaja extract supply, processing, formulation, purification quantification R&D and application, and decades of experience in pharmaceutical R&D, supply chain, manufacturing, commercialization, and regulatory approvals. Chief Executive Officer, Doug Klaiber, is joined by Chief Commercial Officer, Juan Jose Albarran, and Chief Operating Officer, Hans Konsens. The team was recently rounded out by three robust additions including Chief Scientific Officer Bruce Forrest, MD, MBA; Vice President of Regulatory Affairs Jack Love, PhD; and Vice President of Business Development, Stein Lokstad. “Bruce, Jack and Stein bring unparalleled leadership expertise, insights and connections gleaned from their decades working at the likes of companies such as Pfizer and Brenntag Biosector,” said Doug Klaiber, Chief Executive Officer, Q-VANT Biosciences. “Their experience in successfully bringing some of the world’s leading vaccines and adjuvants to market will be invaluable as we scale our efforts to produce as much of this highly valuable adjuvant as is needed.” QS-21 is traditionally extracted from the bark of mature trees native to Chile known as the Quillaja saponaria -- a harvesting process that negatively impacts the forest and the sustainability of the resource. Today, with regulatory restrictions on deforestation of this tree, and projected demand for QS-21 in the billions of doses annually, shortages of QS-21 are affecting the pharmaceutical market’s ability to meet the surging need for vaccine dosages globally. Q-VANT’s Q-SAP™ (Quillaja Sustainable Adjuvant Platform) is a technology platform combining computational learning techniques and a proprietary multi-step purification process to systematically enhance Quillaja sourcing options and to drive extremely effective outputs. The first of its kind, Q-SAP enables Q-VANT to obtain adjuvant products from a wide range of Quillaja-based plant materials, which can increase production volumes by as much as 1,000, leading to billions of doses in a 100% sustainable way. “The market opportunity has expanded rapidly for QS-21 as an adjuvant, especially with the race to research, develop and produce vaccines to combat COVID-19,” said Juan Jose Albarran, Chief Commercial Officer, Q-VANT Biosciences. “Our technology is not only able to fulfill the growing demand for QS-21, but also do it in a fully sustainable way which protects the forest and long-term stability of the supply for the adjuvant.” The company is ramping up its pharma cGMP production and in the process of submitting a Drug Master File (DMF) with FDA in 2022. About Q-VANT Biosciences Q-VANT is a privately held company that has solved the supply chain problem of QS-21 and other Quillaja-based saponin adjuvants for the global human and animal pharmaceutical markets. The company's next-generation technology platform combines computational learning techniques with a proprietary multi-step purification process to increase the supply of QS-21 by more than 1,000% enabling the production of billions of doses annually to meet today's increasing global market demand. Led by a team with unrivaled experience in vaccine and adjuvant development, manufacturing and global regulatory requirements, and with world-class knowledge in Quillaja saponin supply chain, agronomy, extraction and purification, Q-VANT is the first company that is vertically integrated to combine a secured sustainable Quillaja raw material supply with pharma cGMP commercial-scale production of QS-21 and other saponin-based adjuvants. For more information, visit www.q-vant.com. Contact Details Hillary Lima +1 401-490-9700 hillary.lima@svmpr.com Company Website https://q-vant.com/

January 06, 2022 08:00 AM Eastern Standard Time

Article thumbnail News Release

Michael Edwards CEO MedMinder Announcement

MedMinder

MedMinder Systems Inc. (“MedMinder”), the leading fully integrated, end-to-end pharmacy, medication adherence and connected care solution, today announced that Michael F. Edwards has been appointed as Chief Executive Officer. “I am delighted to welcome Mike as our new Chief Executive Officer,” said David Shulkin M.D., Chairman of the Board of Directors of MedMinder. “The COVID-19 Pandemic has highlighted the critical importance of access to medications and remote care. MedMinder is purpose built to assist polychronic patients improve medication adherence and simplify digital care solutions. Mike brings the right set of skills and experience to build upon MedMinder’s platform and take the organization to the next level. Finally, I would like to thank Eran Shavelsky, the founder of MedMinder who led the company from inception into becoming a leading provider of online pharmacy and connected care solutions. Eran’s vision and persistence made MedMinder what it is today.” “I am so proud of the MedMinder team for building such a valuable digital health solution which helps so many people,” said Eran Shavelsky, MedMinder Founder. “I am confident that under Mike’s leadership the company will further grow and expand.” Mike has a passion for helping solve some of the biggest problems in healthcare. As a veteran healthcare executive Mike has built and led high performing organizations within pharmacy, technology and consumer engagement. Prior to joining MedMinder, Mike was Chief Commercial Officer at Truveris. Mike held various executive roles at Optum, a subsidiary of United Health Group (NYSE:UNH). Most recently Mike was President, Commercial Markets at OptumRx. Prior to that role, Mike was part of the executive team at Catamaran where he was instrumental in executing the integration with Optum. Mike held leadership positions at Vitals, Express Scripts and Medco, where he began his healthcare career. Mike holds a bachelor’s degree from Rutgers University and a Masters degree from NJIT in International Business Finance as well as an MBA in the Management of Technology. Mr. Edwards commented: “I’m impressed by MedMinder’s unique ability to engage customers, deliver measurable health outcomes, and simplify the inherent complexity associated with pharmacy care. I look forward to being part of a team with a restless ambition to improve patient experiences and unlock the potential of combining pharmaceutical and digital care.” ABOUT MEDMINDER MedMinder is the leading fully integrated, end-to-end pharmacy, medication adherence and connected care solution for elderly and polypharmacy patients. Founded in 2007 by Eran Shavlelsky, MedMinder currently employs over 150 team members between its Massachusetts and New York locations and is recognized as an ultra-high-growth digital healthcare company. MedMinder’s touch screen-enabled, automatic pill dispenser is the first device on the market capable of delivering medications from its pharmacy directly to patients’ doors in pre-organized daily trays for the entire month. With a customer-first approach, MedMinder is continually innovating to improve and meet the evolving needs of patients, caregivers, practitioners and payors. More information can be found at https://www.medminder.pharmacy. Contact Details MedMinder Systems Inc. Ethan Davis +1 339-777-4662 ethan.davis@medminder.com Company Website https://www.medminder.pharmacy

January 05, 2022 12:00 PM Eastern Standard Time

Article thumbnail News Release

Cortland Biomedical Announces New Product Development Team Appointments to Support Continued Growth

Cortland Biomedical

Cortland Biomedical, a full-service medical textiles product development partner that provides access to a full-spectrum of global engineering, design and manufacturing capabilities, today announced the appointment of three new hires to its New Project Development team. Robert Demaree has been appointed as a Senior Process Engineer. He brings 25 years of experience in various technical roles throughout his career with experience in development of fiber optic cable processes, printed circuit board materials, and electrical generators. He also served as a subject matter expert in composite materials and management of the chemistry group at IMR Test Labs. Rob holds a bachelor’s degree in Mechanical Engineering and a master’s degree in Materials Science and Engineering from Virginia Polytechnic Institute. Tony Maslowski joins the team as a Senior Project Manager to oversee new product development programs and drive projects toward timely completion. He brings more than 30 years of experience in various technical and project management roles throughout his career. He has worked in the chemical and medical device industries, notably with companies such as DePuy and Aesculap. Tony holds a bachelor’s degree in Ceramic Science and Engineering from Penn State and an MBA from Temple University. Additionally, Tony is co-owner of two US patents and holds several certifications in project management. Zach Robbins has been hired as a Textile Process Engineer to help develop processes related to knit and woven fabric product development projects. Zach comes to Cortland with four years of experience in the textile industry, most recently working with finishing and dyeing of knitted products at Gehring Tricot. He holds a bachelor’s degree in Materials Science Engineering – Polymers, Textiles and Fibers from Georgia Tech. Cortland Biomedical’s team nearly doubled in size during the 2021 calendar year, with a particular focus on engineering hires to support its robust new product pipeline. The company is looking to fill additional positions across engineering, manufacturing and administrative support. “We’re proud to be growing in the Cortland Community and continuing to add topnotch talent to further our mission of adding maximum value and innovation to meet our customers’ needs for custom biomedical textile solutions fabricated for their specific medical device applications,” said Eric Brown, Director of Operations, Cortland Biomedical. “We welcome Robert, Tony and Zach to the team and look forward to seeing their contributions to new product development in the year ahead.” In 2021, Cortland completed the transition to its state-of-the-art facility, which construction began on in 2018. Cortland’s ISO 13485:2016 -certified facility on Lime Hollow Rd. has 20,000 sq.ft. of cleanroom manufacturing space, with Class 7 and Class 8 cleanrooms third party-certified to ISO14644. It also features a qualified ASTM Type 1-B water system with sustained monitoring. About Cortland Biomedical Cortland Biomedical custom designs and manufactures high-performance biomedical textile structures leveraging years of experience in medical textile engineering methods including knitting, braiding and weaving. Its thoughtful design concepts challenge the status quo. Cortland Biomedical’s unique combination of advanced equipment and technology, a seasoned medical textile-specific engineering team, and first-rate R&D capabilities allows it to tackle customers’ complex challenges with the innovation and agility expected in the medical device industry. Learn more at cortlandbiomedical.com. Contact Details Jordan Bouclin, SVM Public Relations +1 401-490-9700 Jordan.bouclin@svmpr.com Company Website https://www.cortlandbiomedical.com/

January 05, 2022 10:05 AM Eastern Standard Time

Article thumbnail News Release

The Signs, Diagnosis and Treatment of Lyme Disease Discussed as Part of New, On-Demand Webinar Hosted by Industry-Leading Quidel Corporation

Quidel Corporation

An important public health webinar focused on the Bartonella species, the bacterium that causes Bartonellosis, is now available on demand at https://education.quidel.com/educational-categories. Borrelia burgdorferi, the bacterium that causes Lyme disease, is also discussed as a coinfection on this PACE-accredited webinar, the third in a series hosted by Quidel Corporation (Nasdaq: QDEL) in collaboration with Global Lyme Alliance. Titled “The Diversity of Bartonellosis Manifestations and Challenges to Treatment,” the webinar is conducted by Monica E. Embers, Ph.D.,* associate professor of microbiology and immunology and director of vector-borne disease research at Tulane National Primate Research Center in Covington, Louisiana. Her research at Tulane focuses on the effectiveness of antibiotics and other therapeutics to eradicate Borrelia burgdorferi from the body while also exploring the many avenues related to persistent Lyme disease. Dr. Embers currently serves on the 2021 Tick-Borne Disease Working Group, which was established by Congress as part of the 21st Century Cures Act. Appointed to this position by the U.S. Department of Health and Human Services, the Working Group serves as a federal advisory committee to provide expertise and recommendations regarding all tick-borne diseases, evaluate tick-borne disease research priorities and help ensure coordination between federal agencies. The primary function of the Working Group is the development of a report of findings and recommendations regarding the federal response to tick-borne disease prevention, treatment and research, which it submits to Congress and the Secretary of Health and Human Services. On the webinar, Dr. Embers describes the possible clinical presentations (signs and symptoms) of Bartonellosis; compares Bartonellosis to Lyme borreliosis in terms of detection, persistence and treatment; and identifies research efforts needed to better diagnose and cure Bartonellosis. The timing and relevance for the webinar is particularly important as Lyme disease is on the rise to record numbers throughout the country and potentially affected as many as 476,000 citizens in 2021. Among those invited to view the webinar are physicians; allied health professionals; health researchers; and representatives of physician offices, laboratories, urgent care centers, patient advocacy associations and others interested in the subject. About Quidel Corporation Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names, Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. Quidel’s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world. For more information about Quidel, visit quidel.com. *Dr. Embers receives an honorarium for conducting the webinar sponsored by Quidel. Contact Details breakwhitelight JAMES YEAGER +1 818-264-6812 jim@breakwhitelight.com Company Website http://Quidel.com

January 05, 2022 06:00 AM Pacific Standard Time

Article thumbnail News Release

Academy of Integrative Health and Medicine Signs Cooperation Agreement with PAHO/WHO

Academy of Integrative Health and Medicine

The Academy of Integrative Health and Medicine (AIHM) has signed a cooperation agreement with the Pan American Health Organization, Regional Office of the World Health Organization (PAHO/WHO), and the Biblioteca Regional de Medicina (BIREME), to expand technical and scientific cooperation in traditional, complementary, and integrative medicine. AIHM is the world’s largest interprofessional integrative health association and a leading think tank on the value of transforming healthcare to establish a collaborative, holistic approach to health and wellness. AIHM and PAHO/WHO will work together on projects and activities to promote primary health care, capacity building, evidence synthesis, and information dissemination, through the implementation of existing international instruments within the PAHO/WHO. These include: The PAHO Universal Health Strategy The PAHO Policy on Ethnicity and Health The PAHO Sustainable Health Agenda for the Americas 2018-2030 The WHO Traditional Medicine Strategy 2014-2023 The WHO Framework on People-Centered Integrated Health Services “We are thrilled to be working with PAHO/WHO to advance holistic, integrative health throughout the Americas,” said AIHM Executive Director Tabatha Parker, ND. “When health systems include traditional, complementary and integrative health, it is a win for patients, communities and the planet.” “This agreement is expected to greatly contribute to the collaborative development of information products and services for traditional, complementary, and integrative medicine,” said Dr. Diego Gonzalez, BIREME’s director at the agreement kick-off meeting. Such products are expected to benefit both Latin American and Caribbean countries, as well as the United States and Canada. They will also be available to the larger global community. About AIHM Founded in 1978, the Academy of Integrative Health and Medicine (AIHM) is the leading interprofessional organization for traditional, complementary and integrative health practitioners worldwide. In 2001, AIHM merged with the Academic Collaborative of Integrative Health (ACIH). Together, they are working to advance integrative health on a global scale and transform health and wellness through education, leadership, collaboration, research and advocacy. For more information, visit aihm.org or follow @aihmglobal on Facebook, Instagram, and Twitter. About PAHO/WHO Pan American Health Organization (PAHO) is the specialized international health agency for the Americas and serves as Regional Office for the Americas of the World Health Organization (WHO), the specialized health agency of the United Nations. From its Washington, D.C., headquarters, 27 country offices, and three specialized centers in the region, PAHO promotes evidence-based decision-making to improve and promote health as a driver of sustainable development. For more information, visit paho.org. Contact Details Carol Stevenson +1 661-713-6879 carol@growthledge.com Company Website https://aihm.org

January 05, 2022 08:30 AM Eastern Standard Time

1 ... 237238239240241 ... 301